25.50
-1.44
(-5.35%)
Real-time:
12:09PM EDT
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 25.17 - 26.57 |
| 52 week | 13.59 - 29.37 |
| Open | 25.98 |
| Vol / Avg. | 630,060.00/538,055.00 |
| Mkt cap | 1.26B |
| P/E | - |
| Div/yield | - |
| EPS | -0.21 |
| Shares | 49.22M |
| Beta | 0.78 |
| Inst. own | 103% |
Events
Jul 31, 2012
Q2 2012 Auxilium Pharmaceuticals, Inc. Earnings Conference Call -
Jul 12, 2012
Auxilium Pharmaceuticals, Inc. at JMP Securities Healthcare Conference
Jun 21, 2012
Auxilium Pharmaceuticals, Inc. Annual Shareholder Meeting
Jun 5, 2012
Auxilium Pharmaceuticals, Inc. at Goldman Sachs Healthcare Conference -
Jun 4, 2012
Auxilium Pharmaceuticals, Inc. at Jefferies Global Healthcare Conference -
Jun 4, 2012
Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Phase III Peyronie's Top-line Results -
May 21, 2012
Auxilium Pharmaceuticals, Inc. to discuss the agreement for the Testim� U.S. co-promotion with GlaxoSmithKline LLC - Conference call -
May 16, 2012
Auxilium Pharmaceuticals, Inc. at Bank of America Merrill Lynch Health Care Conference
May 10, 2012
Q1 2012 Auxilium Pharmaceuticals, Inc. Earnings Conference Call -
May 8, 2012
Auxilium Pharmaceuticals, Inc. at Deutsche Bank AG Health Care Conference -
|
More events from DailyFinance »
|
Key stats and ratios
| Q2 (Jun '12) | 2011 | |
| Net profit margin | 9.88% | -12.45% |
| Operating margin | 9.72% | -12.55% |
| EBITD margin | - | -9.92% |
| Return on average assets | 9.67% | -12.08% |
| Return on average equity | 31.54% | -36.81% |
| Employees | 526 | - |
| Carbon Disclosure Rating | - | - |
Address
40 Valley Stream Parkway
MALVERN, PA 19355
United States - Map
+1-484-3215900 (Phone)
+1-484-3215999 (Fax)
MALVERN, PA 19355
United States - Map
+1-484-3215900 (Phone)
+1-484-3215999 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Auxilium Pharmaceuticals, Inc. (Auxilium) is a specialty biopharmaceutical company with a focus on developing and marketing products to predominantly specialist audiences. As of December 31, 2011, the Company markets two products: Testim testosterone gel and XIAFLEX (collagenase clostridium histolyticum). XIAFLEX is an injectable collagenase that the Company in-licensed from BioSpecifics. Under its agreement with BioSpecifics, it has exclusive worldwide rights to develop, market and sell certain products containing XIAFLEX, other than dermal formulations labeled for topical administration. As of December 31, 2011, the Company�s product pipeline includes XIAFLEX for the treatment of Peyronie�s disease (Peyronie�s), which is in Phase III, XIAFLEX for the treatment of Adhesive Capsulitis (Frozen Shoulder syndrome), which is in Phase II, and XIAFLEX for the treatment of edematous fibrosclerotic panniculopathy (cellulite), which is in Phase Ib.
Officers and directors
| Rolf A. Classon | Independent Chairman of the Board | |
| Adrian Adams | President, Chief Executive Officer, Director | |
| James E. Fickenscher | Chief Financial Officer | |
| Benjamin J. Del Tito Jr., Ph.D. | Executive Vice President - Regulatory Affairs and Project Management | |
| Alan J. Wills | Executive Vice President - Corporate Development | |
| Mark A. Glickman | Senior Vice President - Sales | |
| Richard M. Dudek | Senior Vice President - Marketing | |
| Jennifer L. Armstrong | Senior Vice President - Human Resources | |
| Andrew I. Koven | Chief Administrative Officer, General Counsel | |
| Elizabeth Varki Jobes | Chief Compliance Officer |